Triple-negative breast cancer (TNBC) characterizes breast cancers with a lack of estrogen/progesterone receptors and human epidermal growth factor receptor 2 (HER2), making it more difficult to treat than estrogen receptor positive (ER+) breast cancers [1]. This evidence concerns the gene PGR and breast cancer.